Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

GlobeNewswire January 26, 2023

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

GlobeNewswire January 23, 2023

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

GlobeNewswire January 9, 2023

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

GlobeNewswire January 9, 2023

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2023

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

GlobeNewswire December 15, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2022

BioCryst to Present at JMP Securities Hematology & Oncology Summit

GlobeNewswire December 5, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

GlobeNewswire November 28, 2022

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

GlobeNewswire November 10, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2022

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

GlobeNewswire November 1, 2022

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

GlobeNewswire October 24, 2022

BioCryst to Report Third Quarter 2022 Financial Results on November 1

GlobeNewswire October 18, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2022

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

GlobeNewswire September 14, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 6, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire August 31, 2022